Autophagy is a critical cellular adaptive response in tumor formation. Nutritional deficiency and hypoxia exacerbate autophagic flux in established malignancies, promoting tumor cell proliferation, migration, metastasis, and resistance to therapeutic interventions. Pro-survival autophagy inhibition may be a promising treatment option for advanced cancer. Furthermore, excessive or persistent autophagy is cytotoxic, resulting in tumor cell death. Targeted autophagy activation has also shown significant promise in the fight against tumor drug resistance. Several research groups have examined the ability of natural products (NPs) such as alkaloids, terpenoids, polyphenols, and anthraquinones to serve as autophagy inhibitors or activators. The data support the capacity of NPs that promote lethal autophagy or inhibit pro-survival autophagy from being employed against tumor drug resistance. This paper discusses the potential applications of NPs that regulate autophagy in the fight against tumor drug resistance, some limitations of the current studies, and future research needs and priorities.
This work utilizes the anthraquinone (AQ) database to identify potential inhibitors of the RIPK1 protein for developing medicines targeting AP-associated necroptosis. Screening for necroptosis-related genes that play a crucial role in AP is based on the GEO and GSEA databases. An optimum AQ for receptor-interacting protein kinase 1 (RIPK1) inhibition was virtually screened using the Discovery Studio 2019 tool, with a previously described RIPK1 inhibitor (necrostatin-1) as a reference ligand. Using LibDock and CDOCKER molecular docking, an AQ that robustly binds to RIPK1 was identified. The DOCKTHOR web server was used to calculate the ligand–receptor binding energy. The pharmacological properties and toxicity of potential AQ were evaluated using the ADME module and ProTox-II web server. The stability of ligand–receptor complexes was examined using molecular dynamics (MD) simulation. All 12 AQs showed solid binding activity to RIPK1, 5 of which were superior to necrostatin-1. Rheochrysin and Aloe-Emodin-8-O-Beta-D-Glucopyranoside (A8G) were safe RIPK1 inhibitors based on pharmacological characterization and toxicity studies. Additionally, the potential energy of the candidate AQs with RIPK1 was greater than that of the reference ligand, necrostatin-1. MD simulations also showed that the candidate AQs could bind stably to RIPK1 in the natural environment. Rheochrysin and A8G are safe and effective anthraquinones that inhibit the RIPK1 protein. This research takes a first step toward developing RIPK1 inhibitors by screening AQs that have the potential to be more effective than the reference ligand necrostatin-1.
Severe abdominal pain and multiple organ dysfunction are the hallmarks of acute pancreatitis (AP). Opioid medications are effective in alleviating AP patients’ pain; however, they may exacerbate the severity of the condition. This study investigated the potential of bone marrow mesenchymal stem cell-derived small extracellular vesicles (BMSC-sEVs) to inhibit the aggravation effect of opioids through the dual mechanism of gut microbiome-immune crosstalk through data mining and in vivo experiments. Genetic evidence suggests that opioid exposure is linked to gut microbiome dysbiosis, excessive inflammation, and susceptibility to AP. In the rat model, the inflammatory cell infiltration and pancreatic necrosis were exacerbated by the continuously increasing dose of morphine, while these effects were mitigated by antibiotic-driven microbial exhaustion. The primary point is that BMSC-sEVs has the potential to rectify the pancreatic injury that has been exacerbated by morphine by restoring the equilibrium of Bacteroidetes/Pleurophyla and inhibiting CCL3-mediated inflammation. The gut microbiome-immune axis is the primary factor contributing to the aggravation of AP caused by opioids. BMSC-sEVs can be positioned as a novel drug for the treatment of AP, as it effectively regulates gut microbiome-immune crosstalk to coordinate analgesia and inflammation.
Background: Severe acute pancreatitis (SAP) is often associated with life-threatening acute lung injury (ALI), with its pathogenesis being intricately connected to dysregulated inflammatory responses. There is a deficiency of particular treatment options. Dexmedetomidine (DEX), a highly selective α2-adrenergic receptor (α2-AR) agonist, demonstrates not only sedative effects but also possesses anti-inflammatory and organ-protective properties. However, the mechanisms through which DEX exerts its effects in SAP and related pulmonary disorders remain uncertain. Methods: A rat SAP model was established via retrograde injection of 5% sodium taurocholate into the biliopancreatic ducts, with DEX intervention and positive control groups included. The effects of DEX on pathological damage to pancreatic and lung tissues, serum inflammatory factors, and pulmonary edema were evaluated in vivo. In vitro, lipopolysaccharide (LPS) stimulation of human umbilical vein endothelial cells (HUVECs) was used to model an inflammatory environment. Transcriptome sequencing, single-cell RNA sequencing data analysis, protein-protein interaction network construction, molecular docking, and molecular biology techniques were employed to investigate the action targets of DEX and its regulatory effects on the absent in melanoma 2 (AIM2) inflammasome signaling pathway. Results: DEX therapy attenuated the pathological injury to pancreatic and pulmonary tissues in SAP rats, decreased serum concentrations of amylase, interleukin-1 beta, and tumor necrosis factor-alpha, and suppressed pulmonary edema. Transcriptomic analysis revealed that DEX could partially reverse the disorder in lung tissue gene expression profiles induced by SAP and identified the “DEX target gene set”. Bioinformatics analysis identified AIM2 as the core target, and molecular docking indicated that DEX could bind to AIM2 effectively. Single-cell RNA sequencing analysis revealed that the target gene set was specifically highly expressed in endothelial cells. DEX inhibited the activation of AIM2 and Caspase-11, as well as the phosphorylation of the nuclear factor kappa-B signaling pathway in lung tissue and endothelial cells. It also decreased the expression of vascular cell adhesion protein-1 and matrix metalloproteinase-9 in lung tissue. In addition, AIM2 knocdown blocked LPS-induced apoptosis in HUVECs, and DEX showed no further inhibitory effect. Conclusion: This study identifies a novel mechanism in which DEX may alleviate pyroptosis of endothelial cells by targeting and inhibiting AIM2 inflammasome activation, thereby improving SAP-ALI.